Thursday, August 14 11:17:22
NovaUCD spin-in, HiberGene Diagnostics, today said it has licensed new technology that will bring its fight against infectious diseases such as Meningitis to a global stage.
HiberGene Diagnostics Limited, a private Irish diagnostics company focussed on applying molecular technology to the infectious disease segment of the diagnostic market, today announced that it has secured a licence to use Eiken Chemical Company's LAMP (Loop Mediated Isothermal Amplification) enabling technology.
The licence grants HiberGene non-exclusive worldwide rights for the development, manufacture and marketing of diagnostic products for human infectious diseases using LAMP technology. The consideration comprises a licence fee and royalty payments. Financial details were not disclosed.
HiberGene uses the LAMP enabling technology to develop its first two products, which are molecular tests for Meningitis and Group B Streptococcus (GBS).
Both tests are highly accurate and rapid, producing positive results in less than ten minutes, which makes them ideal for use in a range of clinical and patient care environments.
Brendan Farrell, Executive Chairman of HiberGene said, "LAMP is an excellent technology and perfect for the rapid detection of human infectious diseases. With this licence now secured, we can begin manufacturing and marketing our Meningitis and Group B streptococcus products while also developing a range of other tests for human infectious diseases."
For more visit: www.businessworld.ie